Trial Profile
Phase II Trial of Gemcitabine and ISIS 2503 in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2005
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; ISIS 2503 (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 15 Sep 2005 New trial record.